The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
Transition Therapeutics Inc (TTHI)

Transition Therapeutics is a biopharmaceutical company based in Canada. Co. is engaged in developing therapeutics for central nervous system (CNS) and metabolic disease indications. Co.'s technologies are focused on the treatment of Alzhemier's disease and diabetes. Co.'s products include ELND005 (AZD-103) for the treatment of Alzheimer's disease; TT-301 and TT-302 which may have a therapeutic effect on diseases including arthritis, Alzheimer's disease, traumatic brain injury, intracerebral haemorrhage, and others; and TT401/402 for the treatment of diabetes.

Company Name:  Transition Therapeutics Inc
Website:  www.transitiontherapeutics.com
Sector:  Biotechnology
March 29, 2024    10:52 AM Eastern


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Email EnvelopeFree TTHI Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Transition Therapeutics Inc (TTHI) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.